Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of cemdisiran after withdrawal of chronic eculizumab therapy in hemolytic uremic syndrome
2018-004382-13Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- May 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atypical hemolytic uremic syndrome (aHUS) and hemolytic uremic syndrome (HUS) comparing Cemdisiran arm with Placebo arm (2 arms). Primary endpoint: Primary safety and efficacy outcomes. Started May 2021; status: terminated.
02
Drugs
cemdisiran
03
Conditions
atypical hemolytic uremic syndrome (aHUS)hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on 2018-004382-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004382-13.